Veracyte (NASDAQ: VCYT) officer gets PSU vesting, withholds shares

Rhea-AI Filing Summary

VERACYTE, INC. reported an equity award transaction for Chief Scientific & Med Officer Phillip G. Febbo. On February 26, 2026, he acquired 71,806 shares of common stock at $0.00 per share through the vesting of performance-based restricted stock units. According to the award terms, 47,863 PSUs vested on that date and 23,943 additional PSUs are scheduled to vest on December 2, 2026, subject to continued service. To cover tax withholding from the vesting, 24,486 shares were withheld at $38.75 per share, a disposition that did not involve an open-market sale. Following these transactions, he directly owned 136,806 common shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Febbo Phillip G.

Role Chief Scientific & Med Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	71,806	$0.00	--
Tax Withholding	Common Stock	24,486	$38.75	$949K

Holdings After Transaction: Common Stock — 161,292 shares (Direct)

Footnotes (1)

1. Represents shares of common stock acquired by the Reporting Person upon vesting of certain performance based restricted stock units ("PSUs") on February 26, 2026, upon the certification by the Board of Directors of the Issuer of the achievement of the performance goals set forth therein. Of such PSUs, 47,863 PSUs vested on February 26, 2026, and the remaining 23,943 will vest on December 2, 2026, subject to the Reporting Person's continuous service to the Issuer through such date. Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of the PSUs and does not represent a sale.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Febbo Phillip G.

(Last) (First) (Middle)

6000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific & Med Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A(1)		71,806	A	$0	161,292	D
Common Stock	02/26/2026		F(2)		24,486	D	$38.75	136,806	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock acquired by the Reporting Person upon vesting of certain performance based restricted stock units ("PSUs") on February 26, 2026, upon the certification by the Board of Directors of the Issuer of the achievement of the performance goals set forth therein. Of such PSUs, 47,863 PSUs vested on February 26, 2026, and the remaining 23,943 will vest on December 2, 2026, subject to the Reporting Person's continuous service to the Issuer through such date.

2. Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of the PSUs and does not represent a sale.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Veracyte (VCYT) disclose in this Form 4 for Phillip G. Febbo?

Veracyte disclosed that Chief Scientific & Med Officer Phillip G. Febbo received 71,806 common shares from the vesting of performance-based restricted stock units, with some shares withheld to cover tax obligations tied to the vesting event.

How many Veracyte (VCYT) shares did Phillip G. Febbo acquire in this transaction?

Phillip G. Febbo acquired 71,806 Veracyte common shares on February 26, 2026 through the vesting of performance-based restricted stock units, reflecting stock-based compensation rather than an open-market purchase of the company’s shares.

Why were some of Phillip G. Febbo’s Veracyte (VCYT) shares disposed of in this filing?

The filing shows 24,486 Veracyte shares were withheld at $38.75 per share to satisfy Febbo’s tax withholding obligations from the PSU vesting, and the company states this withholding does not represent a market sale of shares.

What future vesting remains for Phillip G. Febbo’s Veracyte (VCYT) PSUs?

The document states that 23,943 performance-based restricted stock units are scheduled to vest on December 2, 2026, contingent on Phillip G. Febbo’s continuous service to Veracyte through that date under the award’s terms.

How many Veracyte (VCYT) shares does Phillip G. Febbo own after these transactions?

After the PSU vesting and tax withholding share disposition, Phillip G. Febbo directly owns 136,806 shares of Veracyte common stock, as reflected in the post-transaction ownership figure in the Form 4 disclosure.